TITLE

Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices--In re Warfarin Sodium Antitrust Litig

AUTHOR(S)
Brooks, Karen
PUB. DATE
June 2005
SOURCE
American Journal of Law & Medicine;2005, Vol. 31 Issue 2/3, p382
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports that the U.S. Court of Appeals for the Third Circuit has rejected challenges to a settlement against DuPont Pharmaceuticals Co. concerning marketing practices. End of a class-action consumer antitrust suit over the marketing of the company's widely used blood thinner, Coumadin; Allegation of the plaintiffs that DuPont's anti-competitive behavior and dissemination of false and misleading information about a lower-priced, readily available generic competitor caused them to purchase the higher priced Coumadin instead of the generic product; Emphasis of the case on the risk of pharmaceutical companies facing competition from generic drug manufacturers to face increased scrutiny for anti-competitive marketing practices.
ACCESSION #
17733181

 

Related Articles

  • AN AMERICAN DRUG PROBLEM: RECLAIMING CONSUMERS' RIGHTS UNDER THE HATCH-WAXMAN ACT. Hogges-Thomas, Alicia I. // Vermont Law Review;Spring2013, Vol. 37 Issue 3, p737 

    The article sheds light on the consequence of reverse payment settlements among pharmaceutical brand name firms and generic drug manufacturers in context to consumers' rights under the Hatch-Waxman Act. It discusses the U.S. Court of Appeals for the Third Circuit case of in re K-Dur Antitrust...

  • PAYING OFF THE COMPETITION. JORDAN, CHRISTINA MICHELLE // Yingyong Shengtai Xuebao;Jan2013, Vol. 24 Issue 1, p12 

    The article focuses on the decision of the U.S. Court of Appeals for the Third Circuit regarding the potential antitrust law violation of the settlement agreements between the generic competitors and pharmaceutical manufacturers. It says that the reverse payment settlements between generic drug...

  • Pay-for-Delay Is Heading Toward Supreme Court Again. Serebrov, Mari // BioWorld Today;7/18/2012, Vol. 23 Issue 138, p1 

    The article reports that the U.S. Court of Appeals for the Third Circuit has rejected pay-for-delay settlements between makers of brand and generic drugs, claiming they violate antitrust laws. It relates that a pay-for-delay case brought by Louisiana Wholesale Drug Co. Inc. against Bayer AG and...

  • FDA in the Hot Seat.  // BioWorld Today;7/18/2012, Vol. 23 Issue 138, p8 

    The article reports that the U.S. Court of Appeals for the Third Circuit has rejected pay-for-delay settlements between makers of brand and generic drugs, claiming they violate antitrust laws. It relates that a pay-for-delay case brought by Louisiana Wholesale Drug Co. Inc. against Bayer AG and...

  • PAYING OFF THE COMPETITION. JORDAN, CHRISTINA MICHELLE // Litigation News;Fall2012, Vol. 38 Issue 1, p12 

    The article focuses on the decision by the U.S. Court of Appeals for the Third Circuit on the K-Dur Antitrust Litigation. The Court ruled that settlement agreements between pharmaceutical companies and their generic competitors may violate antitrust laws. The Court held that such agreements are...

  • Dismissal Of Class Action RICO Suit Against Aetna On Claims Is Upheld By U.S. Court Of Appeals.  // Insurance Advocate;08/19/2000, Vol. 111 Issue 33, p11 

    Reports on the ruling of the United States Court of Appeals for the Third Circuit on the class action lawsuit filed against Aetna Inc. Allegations against Aetna; Implication of the case.

  • Merck Knocks Pay-for-Delay Ball up to Supreme Court. Serebrov, Mari // BioWorld Today;8/28/2012, Vol. 23 Issue 167, p1 

    The article reports on the move of Merck & Co. Inc. to ask the U.S. Supreme Court to determine whether the reverse settlements violate federal antitrust laws. Three appellate courts upheld the legality of the agreements between brand and generic drugmakers. The U.S. Court of Appeals for the...

  • Appeals Court Rejects Certification Of Market Conduct Class. Koco, Linda // National Underwriter / Life & Health Financial Services;3/26/2001, Vol. 105 Issue 13, p5 

    Reports that the United States Court of Appeals for the Third Circuit reversed a lower court's certification of a nationwide class involving contested market conduct litigation. Overview of the court's ruling; Analysis of the court on the case; Impact of the ruling on the boundaries of market...

  • Victory party. Lentz, Rebecca // Modern Physician;Sep2000, Vol. 4 Issue 9, p3 

    Features the August 2000 dismissal of the class-action lawsuit against Aetna in the case of Maio versus Aetna in the United States Court of Appeals for the 3rd Circuit. Information on the plaintiffs; Details on the case; Impact of the decision in the health care industry.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics